Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. 2011

Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands. l.neefjes@erasmusmc.nl

OBJECTIVE We determined the extent, severity, distribution and type of coronary plaques in cardiac asymptomatic patients with familial hypercholesterolemia (FH) using computed tomography (CT). BACKGROUND FH patients have accelerated progression of coronary artery disease (CAD) with earlier major adverse cardiac events. Non-invasive CT coronary angiography (CTCA) allows assessing the coronary plaque burden in asymptomatic patients with FH. METHODS A total of 140 asymptomatic statin treated FH patients (90 men; mean age 52 ± 8 years) underwent CT calcium scoring (Agatston) and CTCA using a Dual Source CT scanner with a clinical follow-up of 29 ± 8 months. The extent, severity (obstructive or non-obstructive plaque based on >50% or <50% lumen diameter reduction), distribution and type (calcified, non-calcified, or mixed) of coronary plaque were evaluated. RESULTS The calcium score was 0 in 28 (21%) of the patients. In 16% of the patients there was no CT-evidence of any CAD while 24% had obstructive disease. In total 775 plaques were detected with CT coronary angiography, of which 11% were obstructive. Fifty four percent of all plaques were calcified, 25% non-calcified and 21% mixed. The CAD extent was related to gender, treated HDL-cholesterol and treated LDL-cholesterol levels. There was a low incidence of cardiac events and no cardiac death occurred during follow-up. CONCLUSIONS Development of CAD is accelerated in intensively treated male and female FH patients. The extent of CAD is related to gender and cholesterol levels and ranges from absence of plaque in one out of 6 patients to extensive CAD with plaque causing >50% lumen obstruction in almost a quarter of patients with FH.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
December 2022, Atherosclerosis plus,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
November 2016, Atherosclerosis,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
June 2019, Atherosclerosis,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
April 2019, Current opinion in lipidology,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
August 1996, Journal of cardiology,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
November 1983, Klinische Wochenschrift,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
May 2013, Journal of the American College of Cardiology,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
March 2015, The American journal of cardiology,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
May 2023, Circulation,
Lisan A Neefjes, and Gert-Jan R Ten Kate, and Rossi Alexia, and Koen Nieman, and Annette J Galema-Boers, and Janneke G Langendonk, and Annick C Weustink, and Nico R Mollet, and Eric J Sijbrands, and Gabriel P Krestin, and Pim J de Feyter
December 2010, Atherosclerosis,
Copied contents to your clipboard!